Literature DB >> 19230595

The role of the protein-binding on the mode of drug action as well the interactions with other drugs.

Christine Tesseromatis1, Anastasia Alevizou.   

Abstract

Drug transport and disposition are influenced by a non-specific and reversible drug binding to plasma and tissues proteins. Albumin and al acid glycoprotein are the most important transport proteins of the blood. Albumin possesses specific sites for acidic and basic drug binding and can interact with them in the plasma since a third site is trapped only by digoxin. Diseases and stress conditions induce conformational changes either in plasma or in tissue proteins by the synthesis of endogenous substances which can strong interfere with the amount of the free pharmacological effective drug ratio. This may affect the binding of drugs in target molecules inducing significant pharmacokinetic alterations. Stress conditions are associated with FFA increase in serum playing an antagonistic role with other acidic molecules (e.g. ampicillin) to the same binding site. The bounded drug is displaced and freer ratio is available to interact with various organ receptors leading to pharmacological effect enhancement and therefore to side effects manifestation such as seizures. Furthermore conjunctive tissues diseases, ageing, prolonged bleeding, starvation or diseases affecting protein profile, characterized by reduced total plasma proteins, followed by albumin decrease and lessen binding sites lead to more free drug availability enhancing its pharmacological effect. Increased a1-acid glycoprotein the acute phase protein as by heart infraction or liver morbidities (e.g CCl4 intoxication) mainly occupied from basic substances, in the case of cationic drug treatment resulted to the enhancement of them and consequently to pronounced effectiveness. In addition, renal failure reduced free fractions of many acidic drugs. It may be concluded that by narrowed therapeutic index of a medicine, and when drug/drug or drug/disease interactions are anticipated, drug monitoring seems to be necessary for its dosage adjustment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19230595     DOI: 10.1007/BF03190876

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  55 in total

1.  Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels.

Authors:  A Frostell-Karlsson; A Remaeus; H Roos; K Andersson; P Borg; M Hämäläinen; R Karlsson
Journal:  J Med Chem       Date:  2000-05-18       Impact factor: 7.446

2.  Adjuvant arthritis-induced changes on ampicillin binding in serum and tissues under the influence of non-steroidal anti-inflammatory drugs in rats.

Authors:  E Tigka; I Daskala; G Rallis; S Anagnostopoulou; C Tesseromatis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Oct-Dec       Impact factor: 2.441

Review 3.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

4.  Differences in plasma binding of drugs between Caucasians and Chinese subjects.

Authors:  H H Zhou; A Adedoyin; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1990-07       Impact factor: 6.875

5.  Pharmacokinetics of intravenously administered 125I-labelled human alpha 1-acid glycoprotein.

Authors:  F Brée; G Houin; J Barré; J L Moretti; V Wirquin; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

6.  Binding of drugs to human muscle.

Authors:  B Fichtl; H Kurz
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

7.  Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin.

Authors:  Zeljko M Prijovich; Yu-Lin Leu; Steve R Roffler
Journal:  Cancer Chemother Pharmacol       Date:  2006-09-16       Impact factor: 3.333

8.  Mechanisms of ketamine action on lipid metabolism in rats.

Authors:  T Saranteas; N Zotos; E Lolis; J Stranomiti; C Mourouzis; C Chantzi; C Tesseromatis
Journal:  Eur J Anaesthesiol       Date:  2005-03       Impact factor: 4.330

9.  Displacement of bilirubin from adult and newborn serum albumin by a drug and fatty acid.

Authors:  R Ivarsen; R Brodersen
Journal:  Dev Pharmacol Ther       Date:  1989

10.  Pharmaceutical-grade albumin: impaired drug-binding capacity in vitro.

Authors:  Harald Olsen; Anders Andersen; Arve Nordbø; Ulf E Kongsgaard; Ole P Børmer
Journal:  BMC Clin Pharmacol       Date:  2004-03-29
View more
  20 in total

1.  Pregnancy in a patient with congenital analbuminaemia.

Authors:  Hillary Hu; Roshini Nayyar; Lucinda Jean Berglund; Elizabeth Anne Anderson
Journal:  BMJ Case Rep       Date:  2017-02-02

2.  Predictors of Thiopurine Treatment Failure in Biologic-Naïve Ulcerative Colitis Patients.

Authors:  Sudeep Dhoj Thapa; Hiba Hadid; Mohammed Usman; Waseem Imam; Ahmad Hassan; Jason Schairer; Syed-Mohammed R Jafri; Nirmal Kaur
Journal:  Dig Dis Sci       Date:  2015-10-28       Impact factor: 3.199

Review 3.  When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?

Authors:  Stephan T Stern; Marilyn N Martinez; David M Stevens
Journal:  Drug Metab Dispos       Date:  2016-09-26       Impact factor: 3.922

4.  Effect of a Pluronic(®) P123 formulation on the nitric oxide-generating drug JS-K.

Authors:  Imit Kaur; Ken M Kosak; Moises Terrazas; James N Herron; Steven E Kern; Kenneth M Boucher; Paul J Shami
Journal:  Pharm Res       Date:  2014-10-18       Impact factor: 4.200

5.  Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients.

Authors:  Michel Tod; Olivier Mir; Natacha Bancelin; Romain Coriat; Audrey Thomas-Schoemann; Fabrice Taieb; Pascaline Boudou-Rouquette; Stanislas Ropert; Judith Michels; Halim Abbas; Jean Philippe Durand; Alain Dauphin; Michel Vidal; Francois Goldwasser; Benoit Blanchet
Journal:  Pharm Res       Date:  2011-06-21       Impact factor: 4.200

6.  Targeted non-covalent self-assembled nanoparticles based on human serum albumin.

Authors:  Anton Bunschoten; Tessa Buckle; Joeri Kuil; Gary D Luker; Kathryn E Luker; Omgo E Nieweg; Fijs W B van Leeuwen
Journal:  Biomaterials       Date:  2011-10-22       Impact factor: 12.479

7.  Exogenous albumin inhibits sorafenib-induced cytotoxicity in human cancer cell lines.

Authors:  Syu-Ichi Kanno; Katsuyuki Itoh; Naoto Suzuki; Ayako Tomizawa; Shin Yomogida; Masaaki Ishikawa
Journal:  Mol Clin Oncol       Date:  2012-06-27

8.  Serum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor Imatinib.

Authors:  Svenja Beckmann; Thavy Long; Christina Scheld; Rudolf Geyer; Conor R Caffrey; Christoph G Grevelding
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-08-07       Impact factor: 4.077

Review 9.  Interactive association of drugs binding to human serum albumin.

Authors:  Feng Yang; Yao Zhang; Hong Liang
Journal:  Int J Mol Sci       Date:  2014-02-27       Impact factor: 5.923

10.  Artocarpin Induces Apoptosis in Human Cutaneous Squamous Cell Carcinoma HSC-1 Cells and Its Cytotoxic Activity Is Dependent on Protein-Nutrient Concentration.

Authors:  Stephen Chu-Sung Hu; Chi-Ling Lin; Hui-Min Cheng; Gwo-Shing Chen; Chiang-Wen Lee; Feng-Lin Yen
Journal:  Evid Based Complement Alternat Med       Date:  2015-01-14       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.